Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors

Journal of Medicinal Chemistry

Volumn 39, Issue 8, 1996, Pages 1589-1600

  Hopkins, Andrew L ^a   Ren, Jingshan ^a   Esnouf, Robert M ^a,b   Willcox, Benjamin E ^a   Jones, E Yvonne ^a,b   Ross, Carl ^c   Miyasaka, Tadashi ^d   Walker, Richard T ^e   Tanaka, Hiromichi ^d   Stammers, David K ^c   Stuart, David I ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d SHOWA UNIVERSITY   (Japan)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 HYDROXYETHOXY)METHYL] 6 (PHENYLTHIO)THYMINE; 6 BENZYL 1 [(BENZYLOXY)METHYL] 5 ISOPROPYLURACIL; EMIVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TNK 651; UNCLASSIFIED DRUG;

ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG DESIGN; ENZYME INHIBITOR COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS 1; STRUCTURE ACTIVITY RELATION; X RAY DIFFRACTION;

ANTIVIRAL AGENTS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; HYDROGEN BONDING; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029976422     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960056x     Document Type: Article

References (65)

1. Mitsuya, H.; Weinhold, K. J.; Furman, P. A.; St. Clair, M. H.; Nusinoff-Lehrman, S.; Gallo, R. C.; Bolognesi, D.; Barry, D. W.; Broder, S. 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effects of human T-lymphotrophic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 7096-7100.
2. Mitsuya, H.; Broder, S. Inhibition of in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/ lympadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 1911-1915.
3. Yarchoan, R.; Mitsuya, H.; Thomas, R. V.; Pluda, J. M.; Hartman, N. R.; Perno, C. F.; Marczyk, K. S.; Allain, J. P.; Johns, D. G.; Broder, S. In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science 1989, 245, 412-415.
4. Coates, J. A. V.; Cammack, N.; Jenkinson, H. J.; Mutton, I. M.; Pearson, B. A.; Storer, R.; Cameron, J. M.; Penn, C. R. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH-189) both inhibit human immunodeficiency virus replication an vitro. Antimicrob. Agents Chemother. 1992, 36, 202-205.
5. St. Clair, M. H.; Richards, C. A.; Spector, T.; Weinhold, K. J.; Miller, W. H.; Langlois, A. J.; Furman, P. A 3′-Azido-3′-deoxy thymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob. Agents Chemother. 1987, 31, 1972-1977.
6. Fischl, M. A.; Richman, D. D.; Grieco, M. H.; Gottlieb, M. S.; Volberding, P. A.; Laskin, O. L.; Leedom, J. M.; Groopman, J. E.; Mildvan, D.; Schooley, R. T.; Jackson, G G.; Durack, D. T.; King, D.; The AZT collaborative working group. The Efficacy of 3′-azido-3′-deoxythymidine (azidothymidine) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 1987, 317, 185-191.
7. Richman, D. D.; Fischl, M. A.; Grieco, M. H.; Gottleib, M. S.; Volberding, P. A.; Laskin, O. L.; Leedom, J. M.; Groopman, J. E.; Mildvan, D.; Hirsch, M. S.; Jackson, G. G.; Durack, D. T ; Nusinoff-Lehtman, S.; The AZT collaborative working group. The toxicity of azidothymidine (AZT) in treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 1987, 317, 192-197.
8. Larder, B. A.; Kemp, S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246, 1155-1158.
9. Larder, B. A.; Kemp, S. D.; Purifoy, D. J. M. Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity. Proc. Natl. Acad Sci. U.S.A. 1989, 86, 4803-4807.
10. Larder, B. A.; Darby, G.; Richman, D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989, 243, 1731-1734.
11. Baba, M.; Tanaka, H.; De Clercq, E.; Pauwels, R.; Balzarini, J.: Schols, D.; Nakashima, H.; Perno, C.-F.; Walker, R. T.; Miyasaka, T. Highly specific inhibition of human immunodeficiency virus type-1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 1989, 165, 1375-1381.
12. Merluzzi, V. J.; Hargrave, K. D.; Labadia, M.; Grozinger, K.; Skoog, M.; Wu, J C.; Shih, C.-K.; Eckner, K.; Hattox, S.; Adams, J.; Rosenthal, A. S.; Faanes, R.; Eckner, R. J., Koup, R. A.; Sullivan, J. L. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990, 250, 1411-1413.
13. Goldman, M. E.; Nunberg, J. H.; O'Brien, J. A.; Quintero, J. C.; Schleif, W. A.; Freund, K. F.; Gaul, S. L.; Saari, W. S.; Wai, J. S.; Hoffman, J. M.; Anderson, P. S.; Hupe, D. J.; Emini, E. A.; Stern, A. M. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6863-6867.
14. Romero, D. L.; Busso, M.; Tan, C.-K.; Reusser, F.; Palmer, J. R ; Poppe, S. M.; Aristoff, P. A.; Downey, K. M.; So, A. G.; Resnick, L.; Tarpley, W. G. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8806-8810.
15. Pauwels, R.; Andries, K.; Desmyter, J.; Schols, D.; Kukla, M. J.; Breslin, H.J.; Raeymaeckers, A., Gelder, J. V.; Woestenborghs, R.; Heykants, J.; Schellekens, K., Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990, 343, 470-474.
16. Bader, J. P.; McMahon, J. B.; Schultz, R. J.; Narayanan, V. L.; Pierce, J. B.; Harrison, W. A.; Weislow, O. S.; Midelfort, C. F.; Stinson, S. F.; Boyd, M. R. Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus replication. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6740-6744.
17. Frank, K. B.; Noll, G. J.; Connell, E. V.; Sim, I. S. Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4,5,1-jk]-[1,4]-benzodiazepine-2-(1H)-thioine compound R82150. J. Biol. Chem. 1991, 266, 14232-14236.
18. Althaus, I. W.; Chou, J. J.; Gonzales, A. J.; Deibel, M. R.; Chou, K.-C.; Kezdy, F. J.; Romero, D. L.; Aristoff, P. A.; Tarpley, W. G.; Reusser, F. Steady-state kinetic studies with the nonnucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J. Biol. Chem. 1993, 268, 6119-6124.
19. Spence, R. A.; Kati, W. M.; Anderson, K. S.; Johnson, K. A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267, 988-993.
20. Kohlstaedt, L. A.; Wang, J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
21. Smerdon, S. J.; Jager, J.; Wang, J.; Kohlstaedt, L. A.; Chirino, A. J.; Friedman, J. M.; Rice, P. A.; Steitz, T. A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3911-3915.
22. Ren, J. S.; Esnouf, R.; Garman, E.; Jones, Y.; Somers, D.; Ross, C.; Kirby, I.; Keeling, J.; Darby, G.; Stuart, D.; Stammers, D. High resolution structure of HIV-1 RT: insights from four RT-inhibitor complexes Nature Struct. Biol. 1995, 2, 293-302.
23. Ding, J.; Das, K.; Tantillo, C.; Zhang, W.; Clark, A. D. J.; Jessen, S.; Lu, X.; Hsiou, Y.; Jacobo-Molina, A.; Andries, K.; Pauwels, R.; Moereels, H.; Koymans, L.; Janssen, P. A. J.; Smith, R. H. J.; Kroeger Koepke, R.; Michejda, C. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 Å resolution. Structure 1995, 3, 365-379.
24. Ding, J.; Das, K.; Moereels, H.; Koymans, L.; Andries, K.; Janssen, P. A. J.; Hughes, S. H.; Arnold, E. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nature Struct. Biol. 1995, 2, 407-415.
25. Ren, J. S.; Esnouf, R.; Hopkins, A.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure 1995, 3, 915-926.
26. Yuasa, S.; Sadakata, Y.; Takashima, H.; Sekiya, K.; Inouye, N.; Ubasawa, M.; Baba, M. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442. Mol. Pharmacol. 1993, 44, 895-900.
27. Richman, D.; Shih, C.-K.; Lowy, I.; Rose, J.; Prodanovich, P.; Goff, S.; Griffin, J. Human immunodeficiency virus type 1 mutants resistant to non-nucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl Acad. Sci. U.S.A. 1991, 88, 11241-11245.
28. Richman, D. D.; Havlir, D.; Corbeil, J.; Looney, D.; Ignacio, C.; Spector, S.A.; Sullivan, J.; Cheeseman, S.; Barringer, K.; Pauletri, D.; Shih, C.-K.; Myers, M.; Griffin, J. Nevirapineresistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 1994, 68, 1660-1666.
29. Schinazi, R.; Larder, B.; Mellors, J. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News 1994, 2, 72-75.
30. Bebenek, K.; Kunkel, T. A. The fidelity of retrovial reverse transcriptase. In Reverse Transcriptase; Skalka, A. M., Goff, S. P., Eds.; Cold Spring Harbor Press: New York, 1993; pp 85-102.
31. Wei, X.; Ghosh, S. K.; Taylor, M. E.; Johnson, V. A.; Emini, E. A., Deutsch, P.; Lifson, J. D.; Bonhoeffer, S.; Nowak, M. A.; Hahn, B. H.; Saag, M. S.; Shaw, G. M. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373, 117-122.
32. Coffin, J. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267, 483-489.
33. Larder, B. A. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 1992, 36, 2664-2669.
34. Larder, B. A. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol 1994, 75, 951-957.
35. Pauwels, R.; Andries, K.; Debyser, Z.; Van Daele, P.; Schols, D.; Stoffels, P.; De Vreese, K.; Woestenborghs, R.; Vandamme, A.-M.; Janssen, C. G. M.; Anne, J.; Cauwenbergh, G.; Desmyter, J.; Heykants, J.; Janssen, M. A. C.; De Clercq, E.; Janssen, P. A. J. Potent and highly selective HIV-1 inhibition by a new series of α-anilinophenylacetamide α-APA derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 1711-1715.
36. Hargrave, K. D.; Proudfoot, J. R.; Grozinger, K. G.; Cullen, E.; Kapadia, S. R.; Patel, U. R.; Fuchs, V. U.; Mauldin, S. C.; Vitous, J.; Behnke, M. L.; Klunder, J.M.; Pal, K.; Skiles, J. W.; McNeil, D. W.; Rose, J. M.; Chow, G. C.; Skoog, M. T.; Wu, J. C.; Schmidt, G.; Engel, W. W.; Eberlein, W. G.; Saboe, T. D.; Campbell, S. J.; Rosenthal, A. S.; Adams, J Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiaze-pinones. J. Med. Chem. 1991, 34, 2231-2241.
37. Baba, M.; De Clercq, E.; Tanaka, H.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, L; Umezu, K.; Nakashima, H.; Mori, S.; Shigeta, S.; Walker, R. T.; Miyasaka, T. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with HIV-1 reverse trancriptase. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2356-2360.
38. Baba, M.; De Clercq, E.; Tanaka, H.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Umezu, K.; Walker, R. T.; Mori, S.; Ito, M.; Shigeta, S.; Miyasaka, T. Highly potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by a novel series of 6-substituted acyclouridine derivatives. Mol. Pharmacol. 1991, 39, 805-810.
39. Tanaka, H.; Baba, M.; Hayakawa, H.; Sakamaki, T.; Miyasaka, T.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Shigeta, S.; Walker, R. T.; Balzarini, J.; De Clercq, E. A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J. Med. Chem. 1991, 34, 349-357.
40. Baba, M.; Shigeta, S.; Tanaka, H.; Miyasaka, T.; Ubasawa, M.; Umezu, K.; Walker, R. T.; Pauwels, R.; De Clercq, E. Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives. Antiviral Res. 1992, 17, 245-264.
41. Miyasaka, T.; Tanaka, H.; Baba, M.; Hayakawa, H.; Walker, R. T.; Balzarini, J ; De Clercq, E. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 1989, 32, 2507-2509.
42. Baba, M.; Shigeta, S.; Yuasa, S.; Takashima, H.; Sehiya, K.; Ubasawa, M.; Tanaka, H.; Miyasaka, T.; Walker, R. T.; De Clercq, E. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 1994, 38, 688-692.
43. Balzarini, J.; Karlsson, A.; De Clercq, E. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives. Mol. Pharmacol. 1993, 44, 694-701.
44. Seki, M.; Sadakata, Y.; Yuasa, S.; Baba, M. Isolation and characterisation of human immunodeficiency virus type-1 mutants resistant to the non-nucleoside reverse transcriptase inhibitor MKC-442. Antiviral Chem. Chemother. 1995, 6, 73-79.
45. Nicholls, A.; Sharp, K.; Honig, B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 1991, 11, 281-296.
46. Rodgers, D. W.; Gamblin, S. J.; Harris, B. A.; Ray, S.; Culp, J. S.; Hellmig, B.; Woolf, D. J.; Debouck, C.; Harrison, S. C. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 1222-1226.
47. Esnouf, R.; Ren, J. S.; Ross, C.; Jones, Y.; Stammers, D.; Stuart, D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside Inhibitors. Nature Struct. Biol. 1995, 2, 303-308.
48. Tanaka, H.; Baba, M.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Synthesis and anti-HIV-1 activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). J. Med. Chem. 1991, 34, 1394-1399.
49. Tanaka, H.; Baba, M.; Saito, S.; Miyasaka, T.; Takashima, H.; Sekiya, K.; Ubasawa, M.; Nitta, I.; Walker, R. T.; Nakashima, H.; De Clercq, E. Specific anti-HIV-1 "acyclonucleosides" which cannot be phosphorylated: synthesis of some deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 1991, 34, 1508-1511.
50. Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K.; Nitta, I.; Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Structure-activity relationships of 1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine analogues: effects of substituents at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. J. Med. Chem. 1992, 35, 337-345.
51. Tanaka, H.; Takashima, H.; Ubasawa, H.; Sekiya, K.; Nitta, I.; Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Synthesis and antiviral activity of deoxy analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)-thymine (HEPT) as potent and selective anti-HIV-1 agents. J. Med. Chem. 1992, 35, 4713-4719
52. Boyer, P. L.; Currens, M. J.; McMahon, J. B.; Boyd, M. R.; Hughes, S H. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 1993, 67, 2412-2420.
53. Dueweke, T. J.; Pushkarskaya, T.; Poppe, S. M.; Swaney, S M.; Zhao, J. Q ; Chen, I. S. Y.; Stevenson, M.; Tarpley. W. G. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 4713-4717.
54. Baba, M.; De Clercq, E.; Iida, S.; Tanaka, H.; Nitta, I.; Ubasawa, M.; Takashima, H.: Sekiya, K.; Umezu, K.; Nakashima, H.; Shigeta, S.; Walker, R. T.; Miyasaka, T. Anti-HIV-1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives. Antimicrob. Agents Chemother. 1990, 34, 2358-2363.
55. Kleim, J.-P.; Bender, R.; Kirsch, R.; Meichsner, C.; Paessens, A.; Riess, A.G. Mutational analysis of residue 190 of human immunodeficiency virus reverse transcriptase. Virology 1994, 200, 696-701.
56. Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K.; Inouye, N.; Baba, M.; Shigeta, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J. Med. Chem. 1995, 38, 2860-2865.
57. Stammers, D. K.; Somers, D. O'N.; Ross, C. K.; Kirby, I.; Ray, P. H.; Wilson, J. E.; Norman, M.; Ren, J. S.; Esnouf, R. M.; Garman, E. F.; Jones, E. Y.; Stuart, D. I. Crystals of HIV-1 reverse transcriptase diffracting to 2.2 Å resolution. J. Mol. Biol. 1994, 242, 586-588.
58. Otwinowski, Z. Oscillation data reduction program. In Data collection and Processing: Sawyer, L., Isaacs, N., Bailey, S., Eds.; SERC Daresbury Laboratory: Warrington, England, 1993; pp 56-62.
59. Brünger, A. T.; Krukowski, A.; Erickson, J. Slow-cooling protocols for crystallographic refinement by simulated annealing. Acta Crystallogr. 1990, A46, 585-593.
60. Brünger, A. T. X-PLOR Manual, Version 3.1; Yale University: New Haven, CT, 1992.
61. Jones, T. A. Interactive computer graphics: FRODO Meth. Enzymol. 1985, 115, 157-171
62. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
63. Kraulis, P. J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 1991, 24, 946-950.
64. Merritt, E. A.; Murphy, M. E. P. Raster3D version 2.0. A program for photorealistic molecular graphics. Acta Crystallogr. 1994, D50, 869-873.
65. Stuart, D. I.; Levine, M.; Muirhead, H., Stammers, D. K. The crystal structure of cat pyruvate kinase at a resolution of 2.6 Å. J. Mol. Biol. 1979, 134, 109-142.